

III . 研究成果の刊行に関する一覧

論文

1. Kumagai M, Marui A, Tabata Y, Takeda T, Yamamoto M, Yonezawa A, Tanaka S, Yanagi S, Ito-Ihara T, Ikeda T, Murayama T, Teramukai S, Katsura T, Matsubara K, Kawakami K, Yokode M, Shimizu A, Sakata R. Safety and efficacy of sustained release of basic fibroblast growth factor using gelatin hydrogel in patients with critical limb ischemia. Safety and efficacy of sustained release of basic fibroblast growth factor using gelatin hydrogel in patients with critical limb ischemia. *Heart Vessels* in press.
2. Marui A, Kimura T, Nishiwaki N, Mitsudo K, Komiya T, Hanyu M, Shiomi H, Tanaka S, Sakata R; CREDO-Kyoto PCI/CABG Registry Cohort-2 Investigators. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with end-stage renal disease requiring dialysis (5-year outcomes of the CREDO-Kyoto PCI/CABG Registry Cohort-2). *Am J Cardiol*. 2014;114:555-61
3. Minakata K, Bando K, Tanaka S, Takanashi S, Konishi H, Miyamoto Y, Ueshima K, Yasuno S, Ueda Y, Okita Y, Masuda I, Okabayashi H, Yaku H, Okamura Y, Tanemoto K, Arinaga K, Hisashi Y, Sakata R. Preoperative chronic kidney disease as a strong predictor of postoperative infection and mortality after coronary artery bypass grafting. *Circ J*. 2014;78:2225-31
4. Marui A, Kimura T, Nishiwaki N, Mitsudo K, Komiya T, Hanyu M, Shiomi H, Tanaka S, Sakata R; CREDO-Kyoto PCI/CABG Registry Cohort-2 Investigators. Comparison of five-year outcomes of coronary artery bypass grafting versus percutaneous coronary intervention in patients with left ventricular ejection fractions $\leq 50\%$ versus $>50\%$ (from the CREDO-Kyoto PCI/CABG Registry Cohort-2). *Am J Cardiol*. 2014;114:988-96
5. Marui A, Kimura T, Nishiwaki N, Komiya T, Hanyu M, Shiomi H, Tanaka S, Sakata R; CREDO-Kyoto PCI/CABG Registry Cohort-2 Investigators. Three-year outcomes after percutaneous coronary intervention and coronary artery bypass grafting in patients with heart failure: from the CREDO-Kyoto percutaneous coronary intervention/coronary artery bypass graft registry cohort-2. *Eur J Cardiothorac Surg*. 2015;47:316-21
6. 丸井 晃, 坂田 隆造 . 【低心機能例に対する血行再建(PCI vs CABG)】 低左心機能例に対する血行再建 PCI vs CABG わが国でのレジストリーデータを含むこれまでのエビデンス . *日本冠疾患学会雑誌*. 2014;20:67-74
7. Nakagawa, T., Kumakawa, K., Usami, S., Hato, N., Tabuchi, K., Takahashi, M., Fujiwara, K., Sakaki, A., Komune, S., Sakamoto, T., Hiraumi, H., Yamamoto, N., Tanaka, S., Tada, H., Yamamoto, M., Yonezawa, A., Ito-Ihara, T., Ikeda, T., Shimizu A., Tabata Y. and Ito, J. A randomized control clinical trial of topical insulin-like growth factor-1 therapy for sudden deafness refractory to systemic corticosteroid treatment. *BMC Med*. 2014 **12**, 219.
8. Ohashi, S., Kikuchi, O., Tsurumaki, M., Nakai, Y., Kasai, H., Horimatsu, T., Miyamoto, S., Shimizu A., Chiba, T. and Muto, M. Preclinical validation of talaporfin sodium-mediated

- photodynamic therapy for esophageal squamous cell carcinoma. *PLoS ONE* 2014 **9** e103126.
9. Huang, B., Takahashi, K., Jennings, E. A., Puntang-on, P., Kiso, H., Togo, Y., Saito, K., Sugai, M., Akira S., Shimizu, A. and Bessho, K. Prospective signs of cleidocranial dysplasia in Cebpb deficiency. *J. Biomed Sci* 2014 **21** 44.
 10. Kiso, H., Takahashi, K., Saito, K., Togo, Y., Tsukamoto, H., Huang, B., Sugai, M., Shimizu, A., Tabata, Y., Economides, A. N., Slavkin, H. C. and Bessho, K. Interactions between BMP-7 and USAG-1 (uterine sensitization-associated gene-1) regulate supernumerary organ formation. *PLoS ONE* 2014 **9** e96938.
 11. Ariyasu, H., Iwakura, H., Yukawa, N., Murayama, T., Yokode, M., Tada, H., Yoshimura, K., Teramukai, S., Ito, T., Shimizu, A., Yonezawa, A., Kangawa, K., Mimori, T. and Akamizu, T. Clinical effects of ghrelin on gastrointestinal involvement in patients with systemic sclerosis. *Endocrine J.* 2014 **61** 735-742.
 12. Naito-Matsui, Y., Takada, S., Kano, Y., Iyoda, T., Sugai, M., Shimizu, A., Inaba, K., Nitschke, L., Tsubata, T., Oka, S., Kozutsumi, Y. and Takematsu, H. Functional evaluation of activation-dependent alterations in the sialoglycan composition of T cells. *J. Biol. Chem.* 2014 **289**, 1564-1579.
 13. Ashida N, Kishihata M, Tien DN, Kamei K, Kimura T, Yokode M. Aspirin augments the expression of Adenomatous Polyposis Coli protein by suppression of IKK β . *Biochem Biophys Res Commun.* 2014; 446(2):460-464.
 14. Sumi E, Yamazaki T, Tanaka S, Yamamoto K, Nakayama T, Bessho K, Yokode M. The increase in prescriptions of bisphosphonates and the incidence proportion of osteonecrosis of the jaw after risk communication activities in Japan: a hospital-based cohort study. *Pharmacoepidemiol Drug Saf.* 2014;23(4):398-405.
 15. Tien DN, Kishihata M, Yoshikawa A, Hashimoto A, Sabe H, Nishi E, Kamei K, Arai H, Kita T, Kimura T, Yokode M., Ashida N. AMAP1 as a negative-feedback regulator of nuclear factor- κ B under inflammatory conditions. *Sci Rep.* 2014;4:5094.
 16. Horie T, Nishino T, Baba O, Kuwabara Y, Nakao T, Nishiga M, Usami S, Izuhara M, Nakazeki F, Ide Y, Koyama S, Sowa N, Yahagi N, Shimano H, Nakamura T, Hasegawa K, Kume N, Yokode M., Kita T, Kimura T, Ono K. MicroRNA-33b knock-in mice for an intron of sterol regulatory element-binding factor 1 (Srebf1) exhibit reduced HDL-C in vivo. *Sci Rep.* 2014;4:5312.
 17. Tsusaka T, Guo T, Yagura T, Inoue T, Yokode M., Inagaki N, Kondoh H. Deacetylation of phosphoglycerate mutase in its distinct central region by SIRT2 down-regulates its enzymatic activity. *Genes Cells.* 2014;19(10):766-777.
 18. Mikawa T, LLeonart ME, Takaori-Kondo A, Inagaki N, Yokode M., Kondoh H. Dysregulated glycolysis as an oncogenic event. *Cell Mol Life Sci.* 2015.

19. Ono K, Horie T, Nishino T, Baba O, Kuwabara Y, Yokode M, Kita T, Kimura T.
MicroRNA-33a/b in Lipid Metabolism. Circ J. 2015.

著書

20. 丸井 晃, 坂田 隆造. 心血管外科 左主幹部・3 枝病変の冠血行再建術 PCI vs CABG .
Annual Review 循環器. 2014:270-281
21. 坂田 隆造.【臨床医学の展望 2014】 心臓血管外科学 複雑冠動脈病変では CABG が標
準治療に . 日本医事新報. 2014;4685:32-33